Clinical Trial

Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-23
Trial Details
NCT Number NCT07551804
Lead Sponsor Xiamen Amoytop Biotech Co., Ltd.
Conditions Adult Growth Hormone Deficiency
Enrollment 36 participants
Start Date 2026-06-10
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22